Advertisement
Screener

Insight Molecular Diagnostics Inc. (IMDX) Overview

Insight Molecular Diagnostics Inc. (IMDX) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.31; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.12; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.34; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.30; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.42$3.14$4.08$5.29$6.86$8.902025-09-292026-09-29$1.86$3.90$8.18$17.15$35.96$75.392021-09-292026-09-29$1.86$4.55$11.10$27.12$66.22$161.702016-09-292026-09-29$1.86$4.80$12.38$31.93$82.33$212.312015-12-302026-09-29$1.86$4.80$12.38$31.93$82.33$212.312015-12-302026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$3.38
Previous close
$3.18
Change
$0.20
Change (%)
6.29%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

IMDX
-54.93%
S&P 500
(m)

1 year

IMDX
+4.64%
S&P 500
(m)

3 years

IMDX
+8.33%
S&P 500
(m)

5 years

IMDX
-95.21%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.31

-0.42-0.30-0.18-0.060.0631 Mar 2025: estimate (m); actual -0.2631 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.3030 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.3430 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.1231 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.3130 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.31(m)(m)
1 Jan 202631 Mar 2026(m)-0.12(m)(m)
1 Jul 202530 Sept 2025(m)-0.34(m)(m)
1 Apr 202530 Jun 2025(m)-0.30(m)(m)
1 Jan 202531 Mar 2025(m)-0.26(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -1.65

-13.33-10.37-7.40-4.44-1.4731 Dec 2022: estimate (m); actual -13.2531 Dec 2022(m)31 Dec 2023: estimate (m); actual -3.7531 Dec 2023(m)31 Dec 2024: estimate (m); actual -4.6631 Dec 2024(m)31 Dec 2025: estimate (m); actual -1.6531 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-1.65(m)(m)
1 Jan 202431 Dec 2024(m)-4.66(m)(m)
1 Jan 202331 Dec 2023(m)-3.75(m)(m)
1 Jan 202231 Dec 2022(m)-13.25(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 0.24M ■ Earnings -11.26M — Profit margin -4711.30%

-15.88M-13407.3%0.03M-8141.3%15.93M-2875.4%31.83M2390.5%30 Sept 2025: revenue 0.26M; earnings -10.85M; profit margin -4174.62%30 Sept 202531 Dec 2025: revenue 1.14M*; earnings 27.22M*; profit margin 2389.53%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 0.03M; earnings -4.29M; profit margin -13406.25%31 Mar 202630 Jun 2026: revenue 0.24M; earnings -11.26M; profit margin -4711.30%30 Jun 2026

31 Dec 2025 ■ Revenue 4.05M ■ Earnings -0.05M — Profit margin -1.24%

-82.14M-7610.8%-50.33M-5074.0%-18.52M-2537.1%13.29M-0.2%31 Dec 2022: revenue 0.96M; earnings -72.90M; profit margin -7609.81%31 Dec 202231 Dec 2023: revenue 1.50M; earnings -0.03M; profit margin -1.85%31 Dec 202331 Dec 2024: revenue 1.88M; earnings -0.06M; profit margin -3.23%31 Dec 202431 Dec 2025: revenue 4.05M; earnings -0.05M; profit margin -1.24%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$3.38(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$3.38High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning IMDX

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$812.78K
Profit margin
48.67%
Return on assets · 12 month
2.03%
Index membership
(m)
Employees
110.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
280.06K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-18.36%*
Total return · month
-18.16%*
Total return · quarter
-37.64%*
Total return · half year
-5.06%*
Total return · year to date
-54.93%*
Total return · 1 year
4.64%*
Total return · 3 years
8.33%*
Total return · 5 years
-95.21%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$1.67M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Insight Molecular Diagnostics Inc. Overview

View more →

(m)

(m)

SEC CIK
1642380
Industry (SIC)
2835 In Vitro & In Vivo Diagnostic Substances
Country of operation
United States
Business address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, Tennessee, 37217, United States
Fiscal year end
1231
Phone
949-409-7600

Similar stocks

Stock NameCountryMarket CapPE Ratio
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92